As the Behavioral Science Lead for the Disease Interception Accelerator (DIA), Kevin Wildenhaus leads the behavioral science innovation and research efforts for the DIA and its venture focus areas. He is also heading work in perinatal depression to intercept the disease prior to its impact on mother and infant.
Prior to joining the DIA, Kevin held a similar role in Johnson & Johnson (J&J) Consumer Research & Development (R&D), providing key insights to drive product adherence/compliance and health habit development across the portfolio of J&J Consumer Brands. He has a strong track record in leveraging technology to deliver scalable, effective health interventions, an important experience that will bring valuable insights to the disease interception strategy. For example, as Head of Behavioral Science for SocialWealth, a health technology company, Kevin led the development of the first consumer-focused mHealth application certification standards and review process for use by health plans and retailers.
Before joining J&J, Kevin served as Senior Director, Science and Innovation at HealthMedia, Inc. and Wellness & Prevention Inc., where he led a clinical team in developing and researching individually tailored, digital health coaching solutions to improve lifestyle behaviors and manage chronic conditions. In addition to his expertise in health behavior change, Kevin has also served as Team Psychologist for a professional football team since 2001.
Kevin joins the DIA with more than 25 years of experience in health psychology, behavioral science and the use of technology to drive engagement and clinically proven behavior change. He has authored numerous peer-reviewed scientific articles and thought leadership white papers, as well as several academic book chapters in psychology. In addition, Kevin has conducted more than 75 keynote addresses, presentations, workshops and seminars.
Kevin earned his Ph.D. in Clinical Psychology from Wayne State University.